Aneurin Bevan Health Board Medicines & Therapeutics Committee. enewsletter
|
|
- Andrea Jennings
- 5 years ago
- Views:
Transcription
1 Aneurin Bevan Health Board Medicines & Therapeutics Committee August 2013 enewsletter Dear Gwent Prescriber At its last two meetings (23 rd May and 11 th July) ABHB s Medicines & Therapeutics Committee made the following decisions in relation to the ABHB Formulary: ABHB FORMULARY UPDATES ABHB s Drug Formulary is at: BNF section ZONISAMIDE (Zonegran ) for adjunctive use in epilepsy ADDED in accordance with the recommendations in NICE CG137 for adjunctive use in a variety of seizures, and extending to off label use in children. The MTC designated zonisamide Amber without Shared Care in the ABHB Traffic Light system. Use of zonisamide as monotherapy for seizures/epilepsy is NOT recommended: Full prescribing information on zonisamide at: BNF section LINAGLIPTIN (Trajenta ) as mono & combination therapy in T2D ADDED as a Green drug (non specialist initiation appropriate) in accordance with the recommendations in AWMSG 0513: Full prescribing information on linagliptin at: BNF section DAPAGLIFLOZIN ( Forxiga ) as combination therapy in T2D ADDED in accordance with recommendation in NICE TA288 (Type 2 diabetes combination therapy) agreed that for an initial period dapagliflozin should be designated Amber without Shared Care (specialist only initiation) It was agreed that such a designation would allow specialists to get first hand experience prescribing it, prior to the anticipated wider use by non specialists across ABHB Primary Care. Full prescribing information on dapagliflozin at: Link to NICE TA288: BNF section INSULIN DEGLUDEC ( Tresiba ) for diabetes mellitus NOT CONSIDERED In the absence of a submission from Novo Nordisk, Tresiba cannot be endorsed by AWMSG for use in accordance with its licensed indication, as a technology appraisal by AWMSG (or NICE) has not been undertaken. Tresiba should NOT be prescribed routinely within NHS Wales for this indication. 1
2 BNF section Glycopyrronium bromide ( SEEBRI Breezhaler ) for COPD ADDED as a Green drug (non specialist initiation appropriate) in accordance with AWMSG recommendation 0713: Full prescribing information on this new LAMA is at: BNF section DESUNIN VITAMIN D TABLETS (COLECALCIFEROL 20 microgram) ADDED as a Green drug (non specialist initiation appropriate). Desunin TABLETS are the same strength (800 units) and cost as Fultium D3 CAPSULES but do NOT contain soya, arachis oil or gelatine. Full prescribing information on Desunin tablets at: Link to ABHB guidance on Management of Vit D Deficiency in Adults: ABHBprescribingGuidanceFINAL%5BJuly2013%5D.pdf BNF section MIRABEGRON ( Betmiga) for urinary frequency, urgency, & urge incontinence ADDED in accordance with the recommendation in NICE TA290 (Overactive bladder). As clinical experience with beta 3 agonist in OAB was currently limited, and the update to CG40 was due for publication in September 2013, the MTC agreed that for an initial period mirabegron should be designated Amber without Shared Care (specialist only initiation). It was agreed that such a designation would allow specialists to get first hand experience prescribing it, prior to wider use by non specialists across Primary Care. Full prescribing information on mirabegron at: ABHB Formulary options in section Urinary incontinence Duloxetine (Yentreve) [AMBER Traffic Light*] For moderate to severe stress urinary incontinence in women Duloxetine 20mg gastro resistant capsules Duloxetine 40mg gastro resistant capsules *Note non specialist initiation of duloxetine is appropriate for diabetic peripheral neuropathy Oxybutynin [GREEN Traffic Light] Note Immediate Release oxybutynin tablets are recommended as first line antimuscarinic agents for urinary incontinence in ABHB Modified Release and transdermal oxybutynin preparations (Lyrinel XL tablets & Kentera patches) are non Formulary Oxybutynin 2.5mg tablets Oxybutynin 3mg tablets Oxybutynin 5mg tablets Solifenacin (Vesicare) [GREEN Traffic Light] Note solifenacin is a second line antimuscarinic for urinary incontinence (after Immediate Release oxybutynin). Solifenacin 5mg tablets Solifenacin 10mg tablets Tolterodine [GREEN Traffic Light] Note M/R tolterodine 4mg capsules (Detrusitol XL) are non Formulary Tolterodine 1mg tablets Tolterodine 2mg tablets Trospium [GREEN Traffic Light] Note Modified Release trospium capsules (Regurin XL) are non Formulary Trospium chloride 20mg tablets 2
3 BNF section Calcium acetate 1000mg tablets (PHOSEX ) a phosphate binding agent ADDED as a Green drug and in accordance with NICE CG157 (Hyperphosphataemia in chronic kidney disease) which recommends calcium acetate as the first line phosphate binder. Phosex is the calcium acetate preparation used by the Cardiff renal unit and the one currently most prescribed in ABHB Primary Care. Calcium carbonate 1.25g tablets should be reserved for those unable to tolerate calcium acetate. Full prescribing information on Phosex at: OTHER PRESCRIBING NEWS Clinical Effectiveness & Prescribing Programme (CEPP) Details of the current GP scheme are now on the MTC s website at: BNF section AZITHROMYCIN in pulmonary disease New local guidance This prescribing/monitoring guidance has been produced in response to increasing requests to GPs to prescribe long term azithromycin to prevent exacerbations in COPD and bronchiectasis patients, which are both OFF LABEL uses. The 2 page guidance is available at: COPD%26BronchiectasisABHBguidanceFINALJuly2013.pdf GMC s 2013 Good practice in prescribing and managing medicines and devices A brief reminder that this ethical guidance came into effect back in February 2013 and it replaces Good practice in prescribing medicines (2008). Specialists should note that if you recommend that a colleague, for example a junior doctor or GP, prescribes a particular medicine for a patient, you must consider their competence to do so. You must satisfy yourself that they have sufficient knowledge of the patient and the medicine, experience (especially in the case of junior doctors) and information to prescribe. You should be willing to answer their questions and otherwise assist them in caring for the patient, as required. Web version of the GMC guidance is at uk.org/guidance/ethical_guidance/14316.asp And a.pdf version at: uk.org/static/documents/content/prescribing_guidance.pdf BNF section 14.4 VARICELLA ZOSTER VACCINE The shingles vaccination programme will begin on 1 September 2013, with eligibility based on a person s age on that date (see Table): 3
4 The programme will offer routine vaccination to all those aged 70 years on 1 September 2013, and a catch up programme for older cohorts each year (1 September to 31 August), starting with those aged 79 years on 1 September As the vaccine s effectiveness diminishes with age it is not recommended for people 80 years. To ensure adequate supplies of vaccine for each year of the programme, and given the short shelf life of the product, the vaccine ( Zostavax ) has been procured centrally for the UK. Link to CMO s letter: BNF section A2 Prescribing SIP FEEDS Further to the item in the MTC s spring enewsletter, the 2010 comprehensive local guidelines for the Treatment of Under Nutrition in the Community (25 pages) has now been updated. The advice it includes on prescribing sip feeds is also available as a separate 2 page guide titled Which Oral Nutritional Supplement (ONS) to prescribe? This short guide sets out a pathway for prescribers initiating sip feeds as well as suggested products for a 7 day trial on an acute prescription (with costs), and a ready reckoner for 28 day supplies (again with costs). All the patient advice leaflets (e.g. on how to fortify food and make nourishing drinks and snacks) have now been brought together into a single 8 page booklet titled FOOD FIRST AD VICE All these resources are all available at: Should ALL clinical trial results be reported? If you believe that drugs companies publish only a fraction of their results and keep much of the information to themselves then you should be interested in signing the petition at: This petition is part of the campaign to get all clinical trials registered and all results publically reported. The campaign has the support of a number of eminent organisations including the MRC. 4
5 BNF section STRONTIUM ranelate (Protelos ): risk of serious cardiac disorders restricted indications, new contraindications, and warnings Following the recent advice on strontium from the MHRA (DSU April 2013 vol 6, issue 9: S1) the guidance below has been obtained from the relevant ABHB clinicians: 1. Strontium should be withdrawn in Primary Care from patients with the following underlying conditions: Uncontrolled high blood pressure; ischaemic heart disease (such as angina or MI); peripheral arterial disease; cerebrovascular disease. 2. The MHRA advice states that Healthcare professionals should review patients at a routine appointment and consider whether or not to continue treatment. This assessment should be informed by a review of the length of therapy, supported by the use of a fracture risk assessment tool (FRAX/Qfracture) and/or consideration of a repeat DEXA scan. 3. If strontium is withdrawn from a patient and alternative treatment is required, then oral bisphosphonate should be considered and initiated in Primary Care. If the patient has tried bisphosphonate and either been intolerant (worth trying 2 different bisphosphonates as some patients tolerate one bisphosphonate better than another) of it or failed it, then realistically the following options are available: Calcium / vitamin D alone only indicated as monotherapy in the elderly infirm institutionalized patients; Raloxifene only really a good option in younger postmenopausal patients with spinal osteoporosis/ fractures without a history of peripheral or hip fracture (no evidence to support its use in hip fracture patients). Denosumab (Prolia) / IV bisphosphonate / PTH therapy all of which will be assessed for and initiated by Secondary Care. 4. Once oral bisphosphonate have tried without success (point 3 above), then it may be appropriate for these patients to be referred to the osteoporosis clinic for either written advice or out patient consultation. If this is felt necessary please fax the query to Rheumatology (fax number ) marked with the heading STRONTIUM QUERY to ensure it is passed to the appropriate clinician for an early decision. The full version of the ABHB guidance can be found at: Full updated prescribing information on strontium at: BNF section Oral KETOCONAZOLE don t use for fungal infections In July 2013 the EMA s Committee for Medicinal Products for Human Use has said that oral medicines containing ketoconazole (Nizoral ) should no longer be used for the treatment of fungal infections. The decision was reached because of the high level of liver injury associated with oral ketoconazole and in view of the currently available alternative antifungals. The decision is only on oral products. Shampoos and creams containing ketoconazole are not affected by the decision. The MHRA s Press Release is at: New From AWMSG Proton Pump Inhibitor & Dyspepsia Educational Pack This pack, endorsed by AWMSG, aims to support the appropriate prescribing of PPIs by providing a practical approach for the initiation and review of PPI prescribing. It includes examples of support material which can be used or adapted for this purpose. 5
6 Feedback on any item in this enewsletter is welcome. Suggested agenda items for the MTC are also welcome. Follow Trevor Batt Pharmacist & Professional Secretary to: Aneurin Bevan HB Medicines & Therapeutics Committee Aneurin Bevan Health Board Based at Victoria House, Corporation Rd, Newport NP19 0BH Tel: (DIRECT LINE) 6
FORMULARY UPDATES ABUHB s Drug Formulary is at:
Aneurin Bevan University Health Board Medicines & Therapeutics Committee PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber At its last
More informationGWENT FORMULARY DECISIONS
Dear Gwent Prescriber At its last two meetings (9 th September and 21 st October 2010) the Gwent Partnership Medicines & Therapeutics Committee (GPMTC) made the following decisions in relation to the Aneurin
More informationCosting statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women
More informationGWENT FORMULARY DECISIONS
Dear Gwent Prescriber At its last three meetings (12 th January, 1 st March and 19 th April 2012) ABHB s Medicines & Therapeutics Committee (formerly GPMTC) made the following decisions in relation to
More informationThe Management of Overactive Bladder Syndrome with Antimuscarinic Drugs
The Management of Overactive Bladder Syndrome with Antimuscarinic Drugs Author Version Date Consultation Date of Ratification By JPG Shaista Hussain Joint Formulary Pharmacist V2 16.09.2014 Homerton University
More informationFORMULARY UPDATES ABUHB s Drug Formulary is at:
ANEURIN BEVAN UNIVERSITY HEALTH BOARD MEDICINES & THERAPEUTICS COMMITTEE PRESCRIBING enewsletter 28 September 2016 ARCHIVE at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber
More informationESCA: Denosumab for the treatment of osteoporosis in postmenopausal women.
ESCA: Denosumab for the treatment of osteoporosis in postmenopausal women. Specialist details Patient identifier Name Tel: This effective shared care agreement (ESCA) sets out details for the sharing of
More informationFORMULARY UPDATES ABUHB s Drug Formulary is at:
Aneurin Bevan University Health Board Medicines & Therapeutics Committee July 2014 PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationURODYNAMIC STUDIES AN INFORMATION LEAFLET. Written by: Department of Urology. Stockport: Website: w w w. s t o c k p o r t. n h s.
URODYNAMIC STUDIES AN INFORMATION LEAFLET Written by: Department of Urology January 2017 Stockport: 0161 419 5698 Website: w w w. s t o c k p o r t. n h s. u k Tameside: 0161 922 6696/6698 Website: w w
More informationPrimary Care management of Overactive Bladder (OAB)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Primary Care management of Overactive Bladder (OAB) Prescribing Tips All medicines for OAB have similar dose-related efficacy. More than one agent (up
More informationPathway from Fracture or Risk Factor to Treatment
Appendix 6A - Guidance on Diagnosis and Management of Osteoporosis Pathway from Fracture or Risk Factor to Treatment Fragility Fracture = fracture sustained from a low energy fall from standing height
More informationPrescribing of Denosumab (Prolia ) in Wales: Review. Full document
Prescribing of Denosumab (Prolia ) in Wales: Review Full document October 2013 This report has been prepared by a multiprofessional collaborative group, with support from the All Wales Prescribing Advisory
More informationDENOSUMAB SHARED CARE GUIDLINES
DENOSUMAB LICENSING Denosumab (PROLIA ) is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for bone loss associated with hormone ablation in men with
More informationOveractive bladder. Information for patients from Urogynaecology
Overactive bladder Information for patients from Urogynaecology An overactive bladder (OAB) is a very common problem. It can cause distressing symptoms that are difficult to control. These can include
More informationUnderstanding NICE guidance. NICE technology appraisal guidance advises on when and how drugs and other treatments should be used in the NHS.
Understanding NICE guidance Information for people who use NHS services Alendronate, etidronate, risedronate, strontium ranelate and raloxifene for preventing bone fractures in postmenopausal women with
More informationDenosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures
APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,
More informationPRESCRIBING enewsletter
Aneurin Bevan University Health Board Medicines & Therapeutics Committee PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber At its last
More informationNHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: CINACALCET in the management of secondary hyperparathyroidism in adult patients with end-stage renal disease
More informationContinence PGD transdermal oxybutynin Kentera patch 36mg
Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence
More informationSummary of Lothian Joint Formulary Amendments
Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The
More informationS H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationUndergoing a urodynamic investigation
Page 1 of 5 Undergoing a urodynamic investigation Introduction This leaflet is intended for the use of those patients undergoing urodynamics investigations. Definition Urodynamics is a diagnostic test,
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationOveractive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based
Overactive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based upon a medical history, and includes a focused physical exam (abdominal, neurological, pelvic in females and
More informationAdministration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures
Administration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures 2017 18 1. Purpose of Agreement This agreement outlines the expectations
More informationDumfries and Galloway. Treatment Protocol for Osteoporosis
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 REFERRAL CRITERIA FOR DEXA 3 TREATMENT 4 Non-Drug Therapy : for all 4 Non-Drug Therapy : in the
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationInformation about your Urodynamics Test
Gynaecology Department Patient Information Information about your Urodynamics Test This information booklet has been given to you to help answer some of the questions you may have about having an urodynamic
More informationTechnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418
Dapagliflozin in triple therapy for treating type 2 diabetes Technology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418 NICE 2018. All rights reserved. Subject to Notice of rights
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 6 December 2004
Area Drug and Therapeutics Committee Prescribing Supplement No 6 In this issue Drugs currently being considered by the SMC Advice due on 13. Joint Formulary Update. Drugs currently being considered by
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationDrugs for Overactive Bladder (OAB)
ril 2014 Drugs for Overactive Bladder (OAB) FINAL CONSOLIDATED COMPREHENSIVE RESEARCH PLAN July 2015 FINAL COMPREHENSIVE RESEARCH PLAN 2 A. Introduction The objective of the drug class review on drugs
More informationUrodynamic Studies. An information guide
TO PROVIDE THE VERY BEST CARE FOR EACH PATIENT ON EVERY OCCASION Urodynamic Studies An information guide Urodynamic Test After reading this leaflet we hope that you will have a greater understanding about
More informationPatient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015
Patient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015 Claire James, Senior Pharmacist Clinical Effectiveness, Ninewells Hospital Aims To increase awareness and
More informationGuidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION should be recommended
Guidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION Denosumab is suitable for patients with established osteoporosis for both primary and secondary fracture prevention
More informationQuality and Outcomes Framework Programme NICE cost impact statement July Indicator area: Osteoporosis - fragility fracture
Quality and Outcomes Framework Programme NICE cost impact statement July 2011 Indicator area: Osteoporosis - fragility fracture Indicators NM29: The practice can produce a register of patients: 1. Aged
More informationNOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT
NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT Phosphate Binders for the Treatment of Hyperphosphataemia in adults with Chronic Kidney Disease OBJECTIVES To outline referral
More informationPRESCRIPTION PAD Click here to find more
PRESCRIPTION PAD Click here to find more Clinical policy and Formulary news Co-proxamol JEXT Probiotics Denosumab Magnesium aspartate Domicilary care staff and assistance with medicines Recommendations
More informationDumfries and Galloway. Treatment Protocol for Osteoporosis
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 Multiple low trauma vertebral fractures in the absence of myeloma or metastatic disease. 2 T-score
More informationFORMULARY UPDATES ABUHB s Drug Formulary is at:
Aneurin Bevan University Health Board Medicines & Therapeutics Committee PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 September 2015 Dear Gwent Prescriber
More informationNew indicators to be added to the NICE menu for the QOF and amendments to existing indicators
New indicators to be added to the for the QOF and amendments to existing indicators 1 st September 2015 Version 1.1 This document was originally published on 3 rd August 2015, it has since been updated.
More informationTelford and Wrekin Clinical Commissioning Group
Telford and Wrekin Clinical Commissioning Group Agenda Item 9.2 CLINICAL COMMISSIONING GROUP GOVERNANCE BOARD EXECUTIVE SUMMARY DATE: 9 th April 2013 TITLE OF PAPER: Continence pathway and Referral letter
More informationPATIENT INFORMATION LEAFLET. Calcichew* 500 mg Chewable Tablets calcium carbonate
PATIENT INFORMATION LEAFLET Calcichew* 500 mg Chewable Tablets calcium carbonate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationMedicines in Scotland: What s the right treatment for me? Information for patients and the public
Medicines in Scotland: What s the right treatment for me? Information for patients and the public You can read and download this document from our website. We are happy to consider requests for other languages
More informationBarts Health NHS Trust and local GPs Shared Care Guidelines. DENOSUMAB (Prolia) Post menopausal osteoporosis
Barts Health NHS Trust and local GPs Shared Care Guidelines Indication: DENOSUMAB (Prolia) Post menopausal osteoporosis DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name
More informationTREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
More informationEssential Shared Care Agreement Drugs for Dementia
E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient
More informationNational COPD Audit Programme
National COPD Audit Programme Planning for every breath National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme: Primary care audit () 2015 17 Data analysis and methodology Section 4: Providing
More informationDrugs reviewed by the SMC in September 2012 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC
Area Drug and Therapeutics Committee Prescribing Supplement No 62 In this issue Drugs reviewed by the SMC in September 2012 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed
More informationBotox (Botulinum Toxin) injections into the bladder
Botox (Botulinum Toxin) injections into the bladder Information for patients, relatives and carers Department of Urology York Teaching Hospital NHS Foundation Trust For more information or advice, please
More informationPregabalin Prescribing in Primary Care Audit Results 2012/13
Executive summary Pregabalin Prescribing in Primary Care Audit Results 2012/13 Pregabalin is extensively used across Aneurin Bevan Health Board (ABHB). It is the second highest medicine in terms of primary
More informationNHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015)
Title of Project: NHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015) 1 Reason for the review In the UK, low dose aspirin (75mg) is licensed for the prevention of thrombotic
More informationEssential Shared Care Agreement Drugs for Dementia
Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give
More informationGreater Manchester Interface Prescribing Group Shared Care Template
Greater Manchester Interface Prescribing Group Shared Care Template Shared Care Guideline the use of Denosumab for the prevention of osteoporotic fractures in postmenopausal women. Author(s)/Originator(s):
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationAppendix 2 Drug Information
Appendix 2 Drug Information Chemical Name: baclofen (bak-loe-fen) Brand Name: Lioresal (U.S. and Canada) Description: Baclofen acts on the central nervous system to relieve spasms, cramping, and tightness
More informationVolume 8; Number 10 May 2014
Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire
More informationSELF CARE IN URINARY INCONTINENCE
O P I N I O N SelfCare 2011;2(6):160-166 Advancing the study&understanding of self-care JULIAN SPINKS General Practitioner, Medway Primary Care Trust ABSTRACT Urinary incontinence and its associated urinary
More informationPRESCRIPTION PAD. The Newsletter of the Cumbria Area Prescribing Committee. February 2012 No. 18. Click here to find more. News from the MHRA
PRESCRIPTION PAD The Newsletter of the Cumbria Area Prescribing Committee February 2012 No. 18 Click here to find more Clinical policy and Formulary news Lothian changes Targeted Medication Use Reviews
More informationNHS GG&C Introduction of Freestyle Libre flash glucose monitoring system
NHS GG&C Introduction of Freestyle Libre flash glucose monitoring system The Freestyle Libre flash glucose monitoring system is a sensor based, factory-calibrated system that measures interstitial fluid
More informationNorth of Tyne Area Prescribing Committee DECISION SUMMARY North of Tyne Area Prescribing Committee Summary of decisions made regarding new product requests considered at a meeting of the Committee on Tuesday
More informationClinical Guideline Bone chemistry management in adult renal patients on dialysis
Clinical Guideline Bone chemistry management in adult renal patients on dialysis This guidance covers how to: Maintain serum phosphate 0.8 to 1.7mmol/L 1 Maintain serum corrected calcium 2.1 to 2.5mmol/L
More informationLincolnshire Prescribing and Clinical Effectiveness Bulletin
S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 11 No 12, September 2017 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
More informationOxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer
Oxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer Category: Summary: Guideline Adjuvant Bisphosphonate treatment for Post-Menopausal
More informationShared Care Agreement for Donepezil
ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationPrimary hypertension in adults
Primary hypertension in adults NICE provided the content for this booklet which is independent of any company or product advertised Hypertension Welcome NICE published an updated guideline on the diagnosis
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence in women: the management of urinary incontinence in women 1.1 Short title Urinary incontinence in women
More informationOsteoporosis: fragility fracture risk. Costing report. Implementing NICE guidance
Osteoporosis: fragility fracture risk Costing report Implementing NICE guidance August 2012 NICE clinical guideline 146 1 of 15 This costing report accompanies the clinical guideline: Osteoporosis: assessing
More informationLincolnshire Prescribing and Clinical Effectiveness Bulletin
S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 12 No 10, November 2018 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
More informationAnalyses of cost-effective BMD scanning and treatment strategies for generic alendronate, and the costeffectiveness
Analyses of cost-effective BMD scanning and treatment strategies for generic alendronate, and the costeffectiveness of risedronate and strontium ranelate in those people who would be treated with generic
More informationPrescribing Framework for Denosumab (Prolia ) in Osteoporosis
Hull & East Riding Prescribing Committee Prescribing Framework for Denosumab (Prolia ) in Osteoporosis Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) Communication We agree
More informationOutcomes of diabetes care in England and Wales. A summary of findings from the National Diabetes Audit : Complications and Mortality reports
Outcomes of diabetes care in England and Wales A summary of findings from the National Diabetes Audit 2015 16: Complications and Mortality reports About this report This report is for people with diabetes
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes
National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationCHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER
RAND WATER MEDICAL SCHEME RAND WATER MEDICAL SCHEME CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER LIST OF CHRONIC CONDITIONS Conditions covered under s chronic medication benefit are detailed below.
More informationA new model for prescribing varenicline
Pharmacist Independent Prescribers in partnership with A new model for prescribing varenicline Dear Stop Smoking Advisor You will be aware of the stop smoking drug varenicline that goes under the brand
More informationFlu season. Making the most of online appointments. August 2018
Flu season Making the most of online appointments August 2018 Dear colleagues, Over the last four years GP Online Services have been implemented by practices across England. Over 14 million patients -
More informationGWENT FORMULARY DECISIONS
Dear Gwent Prescriber At its last two meetings (13 th October and 24 th November 2011) ABHB s Medicines & Therapeutics Committee (formerly GPMTC) made the following decisions in relation to the ABHB Joint
More informationSaint Mary s Hospital The Warrell Unit. Urodynamic Studies. Information For Patients
Saint Mary s Hospital The Warrell Unit Urodynamic Studies Information For Patients 2 Contents What are urodynamic studies? 4 Who needs them? 4 Special instructions 5 How are the studies performed? 6 After
More informationUrodynamic investigations. Bladder pressure test
Urodynamic investigations Bladder pressure test 01935 384394 What is a Urodynamic investigation? It is a detailed investigation into the way your bladder works. Why do I need this investigation? To determine
More informationManagement of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
More informationReviewing Medicines in at risk patients care homes
Reviewing Medicines in at risk patients care homes Clinical Medication Reviews by Pharmacists in Collaboration with GP Surgeries across Brighton and Hove CCG Liz Butterfield FRPharmS 19th April 2016 NICE:
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA)
WORKING IN PARTNERSHIP WITH EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: ACETYLCHOLINESTERASE-INHIBITORS AND MEMANTINE INDICATION/S COVERED: Dementia in Alzheimers Disease Coastal West Sussex Traffic
More informationShared Care Guideline for Olanzapine (Zyprexa )
Shared Care Guideline for Olanzapine (Zyprexa ) Development Process This guidance has been produced by Sarah Hudson Lead Pharmacist SWYPFT following an AMBER classification status of Olanzapine by the
More informationJob Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due
More informationPatient Guide. This PATIENT GUIDE comes with your Binosto 70mg Effervescent Tablets pack. Please read it carefully.
Patient Guide This PATIENT GUIDE comes with your Binosto 70mg Effervescent Tablets pack. Please read it carefully. BIN-15-002 Patient Leaflet DL (Logo).indd 1 17/12/2015 15:29 Binosto 70mg Effervescent
More informationIMMEDIATE DICLOFENAC NEW CONTRAINDICATIONS AND WARNINGS AFTER A EUROPE-WIDE REVIEW OF CARDIOVASCULAR SAFETY
Finance, EHealth and Pharmaceuticals Directorate Pharmacy and Medicines Division T: 0131-244 2528 E: irene.fazakerley@scotland.gsi.gov.uk 1. Medical Directors 2. Directors of Public Health 3. Directors
More information2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team
More informationSHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) 1. Introduction This protocol describes how patients prescribed medicines for ADHD
More information1. UK List Price of Zoledronic acid (Zoledronate) 5 mg (Aclasta )
Novartis Pharmaceuticals UK Ltd Frimley Business Park Frimley Camberley Surrey GU16 7SR Dr C M Longson Director, Centre for Health Technology Evaluation National Institute for Health and Clinical Excellence
More informationPATIENT GROUP DIRECTION
PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (CHAMPIX ) TO ADULTS OVER 18 YEARS OF AGE BY COMMUNITY PHARMACISTS UNDER THE PUBLIC HEALTH SERVICE - SMOKING CESSSATION SERVICE IN NHS HIGHLAND THE
More informationBNSSG Shared Care Guidance Please complete all sections
NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please
More informationInitial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above
Initial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above 2 or > vertebral fractures Low trauma fracture In past 5 years Risk Factors (table1)
More informationPeterborough Nalmefene Pathway Responsibilities for Specialist Services & GP
Peterborough Nalmefene Pathway Responsibilities for Specialist Services & GP INTRODUCTION/BACKGROUND In November 2014 NICE (National Institute of Clinical Excellence) published the Technology Appraisal
More information